Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)

Launched by FUDAN UNIVERSITY · Jan 29, 2023

Keywords

ClinConnect Summary

The ECTOP-1012 clinical trial is studying a surgical procedure called segmentectomy to treat a specific type of lung cancer called ground glass-dominant invasive lung adenocarcinoma. This trial aims to find out how well this surgery works in helping patients live without the disease for five years after treatment and how it affects their lung function afterward. Participants in the study will undergo segmentectomy, which involves removing the part of the lung that contains the tumor.

To be eligible for this trial, participants should be between 18 and 80 years old, have a specific type of lung nodule that is between 2 and 3 centimeters in size, and have not had previous lung cancer surgeries or treatments like chemotherapy or radiotherapy. The trial is currently recruiting participants of all genders. If you or a loved one meet these criteria and are interested, you can expect to receive detailed information about the study, including the surgical procedure and follow-up care. This trial could provide valuable insights into treating this type of lung cancer effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who sign the informed consent form and are willing to complete the study according to the plan;
• • Aged from 18 to 80 years old;
• • ECOG equals 0 or 1;
• • Not receiving lung cancer surgery before;
• • Confirmed to be invasive lung adenocarcinoma intraoperatively or postoperatively;
• • Ground glass-dominant lung nodules
• • Consolidation-to-tumor ratio (CTR) ranges from 0 to 0.5, and tumor size ranges from 2 to 3cm;
• • cN0 without distant metastasis;
• • Tumors could be completely resected assed by surgeons;
• • Not receiving chemotherapy or radiotherapy before.
• Exclusion Criteria:
• • CTR is not 0-0.5, or size is not 2-3cm;
• • Tumors could not be completely resected assed by surgeons;
• • Not lung adenocarcinoma diagnosed cytologically or pathologically;
• • Receiving lung cancer surgery before;
• • Receiving radiotherapy or chemotherapy.